Breaking Innate PD-1 Inhibitor (PD1i) Resistance Using Epigenetic Modifiers; Antitumor Efficacy and Correlative Analyses of Entinostat Plus Pembrolizumab in Non-Inflamed Metastatic Melanoma (MM)
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2019
Price : $35 *
At a glance
- Drugs Entinostat (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 06 Mar 2019 Status changed from not yet recruiting to recruiting.
- 04 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Feb 2019.
- 17 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Jan 2019.